Immuno-Oncology Program

The Juan Osorio Lab

Research

Juan Osorio
Juan C. Osorio, MD
Assistant Attending Physician; Assistant Member

The Osorio lab investigates the mechanisms underlying antibody-mediated immunity, and how we can leverage these insights to develop durable and effective antibody-based immunotherapies. Our research focuses on harnessing the untapped potential of the innate immune system – particularly the myeloid compartment – to drive antitumor immunity, especially in cancers that are refractory to current T cell-centric approaches. We use an integrated approach that combines humanized mouse models, antibody engineering, and high-dimensional immune profiling to dissect the cellular and molecular pathways behind therapeutic antibody activity. A major emphasis of our work is placed on how antibodies reprogram myeloid cell function, enhance crosstalk with adaptive immunity, and reshape the tumor microenvironment to support sustained immune responses. By integrating mechanistic immunology with therapeutic development, we aim to inform the rational design, optimization, and evaluation of next-generation antibody therapeutics capable of delivering durable clinical benefit.

Projects

  • Mechanisms of antibody-mediated antitumor immunity
  • Regulation of myeloid cell effector function
  • Expanding the therapeutic window of immunomodulatory antibodies
  • Translating myeloid-targeted therapies into the clinic

Publications Highlights

Osorio JC+, Knorr DA, Weitzenfeld P, Blanchard L, Yao N, Baez M, Sevilla C, DiLillo M, Rahman J, Sharma VP, Bromberg J, Postow MA, Ariyan C, Robson ME, Ravetch JV. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. 2025 Aug 14 (Inpress). https://doi.org/10.1016/j.ccell.2025.07.013. +Corresponding author

Gómez-Banoy N, Ortiz EJ, Jiang CS, Dagher C, Sevilla C, Girshman J, Pagano AM, Plodkowski AJ, Zammarrelli WA, Mueller JJ, Aghajanian C, Weigelt B, Makker V, Cohen P, Osorio JC+. Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer. J Clin Invest. 2024 Jun 20;134(17):e180516. doi: 10.1172/JCI180516. PMID: 38900575; PMCID: PMC11364395. +Corresponding author

Osorio JC+, Smith P, Knorr DA, Ravetch JV. The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions. Cancer Cell. 2023 Dec 11;41(12):2051-2065.e6. doi: 10.1016/j.ccell.2023.10.007. Epub 2023 Nov 16. PMID: 37977147; PMCID: PMC10842210. +Corresponding author

View All Publications

People

Juan Osorio

Juan C. Osorio, MD

Assistant Attending Physician; Assistant Member

  • The Osorio Lab studies the mechanisms of antibody-mediated immunity, with a focus on myeloid cell reprograming to advance cancer immunotherapies.
  • MD, Universidad Nacional de Colombia (2011)
osorioj@mskcc.org
Email Address
View physician profile
Physician profile

Members

Carlo Miguel Sevilla
Research Assistant
Chelsea Toussaint
Administrative Assistant

Achievements

  • ASCO Young Investigator Award (2020)
  • Damon Runyon Physician-Scientist Training Award (2021)
  • K08 Career Development Award, National Cancer Institute (2022)
  • Louis V. Gerstner, Jr. Physician Scholars Program (2022)
  • Burroughs Wellcome Fund, Career Awards for Medical Scientists (2025)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Juan C. Osorio discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures